AI Article Synopsis
- Cervical cancer is primarily caused by human papillomavirus (HPV), and treatment options like radiotherapy combined with hyperthermia are considered when patients can't undergo standard chemoradiotherapy.
- The study explored how different temperatures (37-42 °C) and the timing of hyperthermia in relation to ionizing radiation affect DNA damage and cell survival in various HPV-related cervical cancer cell lines.
- Findings showed that a short interval between treatments leads to more unrepaired DNA damage and increased cell death, especially at higher temperatures, although the order of treatments had similar effects on cell survival.
Article Abstract
Cervical cancers are almost exclusively caused by an infection with the human papillomavirus (HPV). When patients suffering from cervical cancer have contraindications for chemoradiotherapy, radiotherapy combined with hyperthermia is a good treatment option Radiation-induced DNA breaks can be repaired by nonhomologous end-joining (NHEJ) or homologous recombination (HR). Hyperthermia can temporarily inactivate homologous recombination. Therefore, combining radiotherapy with hyperthermia can result in the persistence of more fatal radiation-induced DNA breaks. However, there is no consensus on the optimal sequence of radiotherapy and hyperthermia and the optimal time interval between these modalities. Moreover, the temperature of hyperthermia and HPV-type may also be important in radiosensitization by hyperthermia. In this study we thoroughly investigated the impact of different temperatures (37-42 °C), and the sequence of and time interval (0 up to 4 h) between ionizing radiation and hyperthermia on HPV16: SiHa, Caski; HPV18: HeLa, C4I; and HPV: C33A, HT3 cervical cancer cell lines. Our results demonstrate that a short time interval between treatments caused more unrepaired DNA damages and more cell kill, especially at higher temperatures. Although hyperthermia before ionizing radiation may result in slightly more DNA damage, the sequence between hyperthermia and ionizing radiation yielded similar effects on cell survival.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139900 | PMC |
| http://dx.doi.org/10.3390/cancers12030582 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Six-month Rituximab-Lenalidomide regimen in advanced untreated Follicular Lymphoma: SAKK 35/10 Trial 10-year Update.
Blood Adv
January 2025
Ente Ospedaliero Cantonale, Switzerland.
The Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG) conducted the SAKK 35/10 randomized phase-2 trial (NCT0137605) to compare rituximab (R) alone versus R plus lenalidomide (L) as initial treatment for follicular lymphoma (FL). Patients with grade 1-3a FL, requiring systemic therapy, were randomized to either R (n=77; 375 mg/m2 IV x 1, weeks 1-4) or RL (n=77; R on the same schedule and L at 15 mg daily continuously). Responders (evaluated at 10 weeks) repeated R during weeks 12-15 with or without L (for a total of 18 weeks).
View Article and Find Full Text PDFMRD-guided zanubrutinib, venetoclax and obinutuzumab in relapsed CLL: primary endpoint analysis from the CLL2-BZAG trial.
Blood
January 2025
Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); University of Cologne, Faculty of Medicine and University Hos, Cologne, Germany.
The phase 2 CLL2-BZAG trial tested a measurable residual disease (MRD)-guided combination treatment of zanubrutinib, venetoclax and obinutuzumab after an optional bendamustine debulking in patients with relapsed/refractory CLL. In total, 42 patients were enrolled and two patients with ≤2 induction cycles were excluded from the analysis population per protocol. Patients had a median of one prior therapy (range 1-5), 18 patients (45%) had already received a BTK inhibitor (BTKi), seven patients (17.
View Article and Find Full Text PDFState-Level Influenza Hospitalization Burden in the United States, 2022-2023.
Am J Public Health
January 2025
Alexia Couture, A. Danielle Iuliano, Ryan Threlkel, Matthew Gilmer, Alissa O'Halloran, Dawud Ujamaa, Matthew Biggerstaff, and Carrie Reed are with the National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Howard H. Chang is with the Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA.
To develop a method leveraging hospital-based surveillance to estimate influenza-related hospitalizations by state, age, and month as a means of enhancing current US influenza burden estimation efforts. Using data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), we extrapolated monthly FluSurv-NET hospitalization rates after adjusting for testing practices and diagnostic test sensitivities to non-FluSurv-NET states. We used a Poisson zero-inflated model with an overdispersion parameter within the Bayesian hierarchical framework and accounted for uncertainty and variability between states and across time.
View Article and Find Full Text PDFLonger recreational screen time contributes to the risk of age-related macular degeneration: a UK Biobank cohort study and two-sample Mendelian randomisation.
J Glob Health
January 2025
Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: Recreational screen time (RST) has been found to be associated with cognitive decline and neurodegenerative diseases. However, the association between RST and age-related macular degeneration (AMD), an ocular neurodegenerative disease, is still unclear. We aimed to elucidate the association between RST and AMD.
View Article and Find Full Text PDFIntraprocedural Three-Dimensional Imaging Registration Optimizes Magnetic Resonance Imaging-Guided Focused Ultrasound and Facilitates Novel Applications.
Oper Neurosurg (Hagerstown)
November 2024
Department of Neurosurgery, University of Pennsylvania Health System, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Background And Objective: Transcranial magnetic resonance-guided focused ultrasound (MRgFUS) has revolutionized ablative treatment of essential tremor in recent years. However, limitations in precision targeting may account for suboptimal efficacy and significant side effects. We describe a simple intraprocedural three-dimensional image-guided lesion shaping technique that can improve overall outcomes of MRgFUS for essential tremor and facilitate expansion to novel indications.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!